排卵予測装置の世界市場-2022-2029

市場の概要

排卵は、毎月卵巣から卵子が放出される生物学的プロセスです。排卵の前には、女性の体内で黄体形成ホルモン（LH）が血液中に大量に放出され、通常、月経周期の中頃に行われます。排卵予測検査薬は、排卵期前になると尿中のLHの濃度が上昇するため、それを検知するものです。これらの検査により、排卵時期や妊娠可能性のピークを予測します。排卵前期検査薬は、尿中のLH濃度、唾液中の電解質濃度、または使用者の基礎体温をもとに、排卵を予測します。排卵予測装置は、自宅で快適に検査ができ、黄体形成ホルモンと別のホルモン様物質であるエストロゲンの検出をサポートします。

市場力学

妊娠合併症の増加が市場を牽引し、検査の簡単な使用法と入手のしやすさ、妊娠管理および女性の健康の向上、信頼性の高い正確な結果を得るための技術の進歩があります。

排卵予測装置の技術的進歩が市場成長の原動力になると予想されます。

スマートフォンや同様のデバイス用に設計された受胎能力追跡ソフトウェアアプリケーション（アプリ）は、妊娠を希望する女性が性交のタイミングを計るために使用されることが増えています。妊活アプリの多くは、直近の生理日や生理周期など、ユーザーのデータのみをもとに予測を行います。しかし、カレンダーだけでは、妊娠可能な期間や排卵を検知することができないことが判明しています。ある研究では、周期追跡アプリを活用しても、女性の排卵日を正しく特定できる確率はわずか21％であることが判明しました。そのため、排卵検査薬の精度とアプリの手軽さを兼ね備えた排卵可能日の判定方法が、妊娠を希望する女性にとって有用であると考えられます。例えば、The Clearblue Connected Ovulation Test System（Swiss Precision Diagnostics[SPD]GmbH, Geneva, Switzerland）は、女性の家庭用を想定しています。排卵に先行するLHとE3Gレベルの上昇を追跡することにより、受胎可能期を確実に予測することができます。21この検査システムは、Bluetoothでユーザーのスマートフォンに接続することができ、ソフトウェアが女性の月経周期を記録し、その情報をもとにおしっこ検査を行うタイミングを決定します。尿中ホルモン検査は、ホルモンレベルが基準値のときは低レベル、モニターがE3Gレベルの上昇を検知したときは高レベル、LHサージが検知されたときは妊娠可能性のピークという3つの度合いのいずれかを反映するものです。したがって、上記の要因から、予測期間中に市場が牽引されることが予想されます。

抑制要因

排卵検査薬は、排卵を確認するものではなく、排卵に先行する黄体形成ホルモンを特定するものです。排卵誘発剤を使用している場合、排卵検査薬は正しく機能しないです。40歳以上の女性、またはすでに閉経を迎えている女性は、排卵検査薬を使用することができません。排卵検査キットの使用に関する認知度の低さ、およびデバイスを使用する利点が、予測期間中に市場が阻害されると予想される要因です。

COVID-19の影響分析

COVID-19の大流行は、人類が前世紀に直面した最も壊滅的な健康危機です。実行可能な医薬品の選択肢がないため、この病気との戦いに支障をきたしています。現在、COVID-19を治療するための臨床的に認可されたワクチンや医薬品はなく、新規治療法の絶え間ない探求がパンデミックペースで進行しています。さらに、在宅勤務の文化があるため、人々は主に家にいて、仕事から長期離脱していました。また、在宅勤務が主流となり、仕事から解放され、家族と充実した時間を過ごすことができました。この間、妊娠率は上昇し、排卵検査薬市場は活性化しました。地元の小売店が営業していたため、排卵検査薬の不足はありませんでしたが、排卵検査薬の生産量が少なかったため、排卵検査薬市場の需要は減少しました。COVID-19以降、排卵検査薬市場は急成長すると思われます。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 市場影響要因
  • 促進要因
    • 排卵予測装置の技術的進歩が市場成長を促進すると予想されます。
  • 抑制要因
    • 排卵検査キットの使用に関する認知度の低さが市場成長を阻害すると予想されます。
  • 市場機会
  • 影響分析

第5章 産業分析

• ポーターの5つの力
• サプライチェーン
• プライシング分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的な取り組み
• まとめ

第7章 製品タイプ別

• 尿中排卵検査キット
  • テストストリップ法
  • ミッドストリーム法
• 唾液排卵検査薬
• 唾液腺排卵検査キット

第8章 エンドユーザー別

• 病院
• クリニック
• 診断センター
• 不妊治療センター
• 在宅医療
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A（合併・買収）分析

第11章 企業プロファイル

• Swiss Precision Diagnostics GmbH
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Church & Dwight Co. Inc.
• Prestige Consumer Healthcare, Inc.
• Hilin Life Products
• Fairhaven Health LLC
• Geratherm Medical AG
• Piramal Enterprises Ltd.
• Clearblue
• Fertility Focus Limited
• Accuquik

第12章 排卵予測装置の世界市場-DataM

Market Overview

The global ovulation predictors market size was valued around US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of YY% during the forecast period (2022-2029).

Ovulation is a biological process of releasing eggs from the ovary every month. Before ovulation, the female body releases luteinizing hormones (LH) in a large amount into the blood, which usually takes place in the middle of the menstrual cycle. Ovulation predictors detect a rise in LH in urine as its concentration increases before the ovulation phase. These tests predict ovulation time and peak fertility. Ovulation predictors are based on LH levels in urine, electrolyte levels in saliva, or the user's basal body temperature. Ovulation predictors provide the comfort of testing at home and help in the detection of luteinizing hormone along with another hormone-like, estrogen.

Market Dynamics

A rise in pregnancy complications drives the market, easy usage and availability of tests, increased pregnancy management and women's health, and technological advancements for reliable and accurate results.

Technological advancement in ovulation predictors is expected to drive market growth.

Fertility-tracking software applications (apps) designed for smartphones and similar devices are increasingly used to time intercourse by women seeking to conceive. Most fertility apps provide forecasts based entirely on user data, such as the latest menstrual period date and cycle duration. However, using a calendar alone to detect the viable window and ovulation has proved ineffective. One study discovered that by utilizing cycle-tracking apps, the probability of correctly identifying a woman's day of ovulation was only 21%. As a result, a way of determining the viable window that combines the precision of an ovulation test with the ease of an app could be useful to women trying to conceive. For instance, The Clearblue Connected Ovulation Test System (Swiss Precision Diagnostics [SPD] GmbH, Geneva, Switzerland) is intended for home use by women. It may reliably forecast the fertile window by tracking spikes in LH and E3G levels that precede ovulation. 21 The test system can link to the user's smartphone through Bluetooth, where the software records the woman's menstrual cycle and uses this information to determine when to perform the pee tests. The urine hormone test reflects one of three degrees of fertility: low when hormone levels are at baseline, high when the monitor detects increasing E3G levels, and peak fertility when the LH surge is detected. Thus, from the above factors, the market is expected to drive in the forecast period.

Restraint:

However, the ovulation test doesn't confirm ovulation; it simply identifies the Luteinizing hormone that precedes ovulation. If the User is on any fertility drugs, the ovulation test does not function properly. The ovulation test does not function for women over 40 or already approaching menopause. Low awareness regarding using Ovulation test kits and the benefits of using devices are the factors the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic is the most devastating health crisis that humanity has faced in the last century. The lack of viable medicinal options has hampered the fight against the disease. There is currently no clinically licensed vaccine or medicine to treat COVID-19, and the continuous hunt for a novel cure is moving at a pandemic pace. Moreover, because of the work-from-home culture, people mainly stayed at home and had an extended break from work. The respite from their hectic schedules allowed them to spend quality time with their families. Pregnancy rates increased during this time, which boosted the ovulation test kit market. There was no shortage of ovulation test kits because local retailers were open; nonetheless, the low output of ovulation test kits reduced demand in the ovulation test market. Following the post-COVID-19 situation, the ovulation kit test market will likely grow rapidly.

Segment Analysis

Urine-Based Ovulation Test Kit segment is estimated to hold the largest market share in ovulation predictors market.

The urine-based ovulation test kit segment accounted for the largest market share in 2021. The segment benefits because these are more accurate than salivary ferning kits, but they're not foolproof. These are very easy to use and can be bought bulk from any supermarket. Urine-Based Test Ovulation Test Kit comes with test strips or sticks. For instance, Clearblue Easy Fertility Monitor, this monitor detects two hormones, LH and estrogen. It allows for detection on more fertile days than paper tests. Therefore, it has increased the demand for the urine-based ovulation test kit. Thus, from the above factors, the market segment is accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global ovulation predictors market

North America accounted for the largest market share in 2021. Technological advancements in the ovulation predictors, higher adoption of the tests, partnerships and collaborations by the key market players in the region are the factors to drive the market in the forecast period. For instance, a team of Brigham researchers has created a low-cost smartphone gadget that can predict ovulation and aid in family planning using the latest technological advancement. The instrument automatically recognizes fern-like patterns-a hallmark of ovulation-in a saliva sample using microfluidic technology (in which fluids flow through small channels), artificial intelligence (AI), and the pervasiveness of smartphones. The scientists tested the device's effectiveness in the lab using artificial saliva. They validated the results with saliva samples from six patients, achieving higher than 99 percent accuracy in predicting ovulation.

Additionally, through the Real Talk with Conceiving Hood Campaign, actress Jordana Brewster collaborated with Clearblue in April 2021 to raise awareness about the difficulty in conceiving and fertility in women. Therefore, it has increased the adoption of ovulation predictors in the region. Thus, from the above factors, the North America region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the ovulation predictors market are: Swiss Precision Diagnostics GmbH, Hilin Life Products, Fairhaven Health LLC, Geratherm Medical AG, Church & Dwight Co. Inc., Prestige Consumer Healthcare, Inc., Piramal Enterprises Ltd., Clearblue, Fertility Focus Limited, and Accuquik.

Swiss Precision Diagnostics GmbH:

Overview:

Swiss Precision Diagnostics (SPD) was formed as a joint venture between Procter & Gamble (P&G) and Alere (now a part of the Abbott group, since October 2017) to create, using its parent companies complementary strengths, one of the world's foremost organizations in consumer diagnostics. Alere (a wholly owned subsidiary of Abbott) is among the world's leading providers of innovative diagnostic products, renowned for their proven reliability in the professional management of women's health and chronic and infectious disease. SPD is currently a leading home pregnancy and fertility/ovulation test supplier. The company has a strong focus on women's reproductive health, and its goals are in the continuing supply of diagnostic products which are accurate, simple and affordable.

Product Portfolio:

Clearblue Advanced Fertility Monitor: Clearblue Advanced Fertility Monitor is one of the most advanced home method proven to increase a woman's chance of conceiving by up to more than 85% in the first two cycles of use. The monitor reliably identifies the days of the cycle when women are most likely to conceive - these are the days before the day of ovulation when an egg is released from the ovary. Having sexual intercourse on the day of ovulation and the days leading up to ovulation provides the best chances of conceiving. The product consists of a handheld monitor and disposable test sticks. The monitor tells the woman when to test and indicates her level of fertility each day. Two hormones are monitored - estrone-3-glucuronide (E3G), a urinary metabolite of estrogen and luteinizing hormone (LH). By monitoring both hormones, the monitor can identify more fertile days than any other home method. It is a unique innovation for couples who are proactively planning pregnancy. It is simple to use, completely natural and 99% accurate in detecting the LH surge.

The global ovulation predictors market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Technological advancement in ovulation predictors is expected to drive market growth.
  • 4.1.2. Restraints:
    • 4.1.2.1. Low awareness regarding using Ovulation test kits is expected to hamper market growth.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces
• 5.2. Supply Chain
• 5.3. Pricing Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Urine-Based Ovulation Test Kit*
  • 7.2.1.1. Test Strip Method
  • 7.2.1.2. Introduction
  • 7.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.2.1.4. Mid-Stream Method
• 7.3. Saliva-Based Ovulation Test Kit
• 7.4. Salivary Ferning Ovulation Test Kits

8. By End user

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 8.1.2. Market Attractiveness Index, By End user
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Clinics
• 8.4. Diagnostic Centers
• 8.5. Fertility Centers
• 8.6. Homecare
• 8.7. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Swiss Precision Diagnostics GmbH*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Church & Dwight Co. Inc.
• 11.3. Prestige Consumer Healthcare, Inc.
• 11.4. Hilin Life Products
• 11.5. Fairhaven Health LLC
• 11.6. Geratherm Medical AG
• 11.7. Piramal Enterprises Ltd.
• 11.8. Clearblue
• 11.9. Fertility Focus Limited
• 11.10. Accuquik

LIST NOT EXHAUSTIVE

12. Global Ovulation Predictors Market - DataM

• 12.1. Appendix
• 12.2. About Us and Applications
• 12.3. Contact Us